Meeting
2014 ASCO Annual Meeting
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab (BV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).
Authors
Amreen Husain
Genentech, Inc., South San Francisco, CA
Amreen Husain , Yan V. Wang , Rikke Frederiksen , David T. Bollag , Lars Christian Hanker , Belen Ojeda , Maarit Anttila , Enrico Breda , Peter Vuylsteke , Eric Pujade-Lauraine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT00976911
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 5540^)
DOI
10.1200/jco.2014.32.15_suppl.5540
Abstract #
5540^
Poster Bd #
322
Abstract Disclosures
Similar Posters
First Author: Karen Basen-Engquist
Poster
2022 ASCO Annual Meeting
KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.
First Author: Brian M. Slomovitz
Poster
2018 ASCO Annual Meeting
GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.
First Author: Krishnansu Sujata Tewari
Poster
2015 ASCO Annual Meeting
Bevacizumab (BEV) with or after chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (PROC): Exploratory analyses of the AURELIA trial.
First Author: Aristotelis Bamias